Standout Papers

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia 2014 2026 2018 2022 542
  1. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia (2014)
    Dirk Blom, Tomas Hala et al. New England Journal of Medicine

Immediate Impact

13 from Science/Nature 77 standout
Sub-graph 1 of 19

Citing Papers

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
2023 Standout
2 intermediate papers

Works of Phillip D. Toth being referenced

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
2014 Standout
Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia
2001

Author Peers

Author Last Decade Papers Cites
Phillip D. Toth 1214 227 559 373 25 1.8k
Ana Filipa Macedo 945 436 442 518 19 2.0k
A.F.H. Stalenhoef 1216 582 759 136 42 2.2k
Barry Gumbiner 1272 263 1110 294 51 2.6k
Jonathan L. Isaacsohn 1458 571 711 262 50 2.3k
Maud N. Vissers 1564 350 581 175 47 2.5k
Paul L. Canner 1437 853 1096 290 43 2.8k
Jean Charles Fruchart 1558 563 626 179 26 2.7k
Fergus McTaggart 949 158 367 239 33 1.6k
Kathleen Wyne 960 443 954 141 62 2.4k
Kenneth G. Berge 1149 450 951 171 26 1.9k

All Works

Loading papers...

Rankless by CCL
2026